NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer

The following documents are made available to the consultees and commentators:

1. **Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)**

2. **Consultee and commentator comments on the Appraisal Consultation Document** from:

   - Lilly UK (including new evidence on the size of the eligible patient population and the cost effectiveness of pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer)
     - Appendix 1: Application of the supplementary advice on 'End of life' in the context of the size of the cumulative patient population eligible for pemetrexed
     - Appendix 2: Detailed cost-effectiveness response
     - Eligible patient numbers diagram
     - Factual inaccuracies in the Appraisal Consultation Document

   A 'no comments' response was received from the Royal College of Nursing, the Royal College of Pathologists and the Department of Health.

3. **Comments on the Appraisal Consultation Document from experts:**

   - Dr Riyaz Shah, clinical expert nominated by Lilly UK
   - Dr Yvonne Summers, clinical expert nominated by the Royal College of Physicians (comments endorsed by the Royal college of Physicians)

4. **Comments on the Appraisal Consultation Document received through the NICE website**

5. **Additional evidence**
   - Review of additional evidence submitted by Liverpool Reviews and Implementation Group

Any information supplied to NICE which has been marked as confidential has been redacted. All personal information has also been redacted.